Fed. Circ. Looks At Early Statements In Neulasta Patent Row
Federal Circuit judges on Tuesday questioned how much weight courts should put on statements made in the prelitigation process by companies making copycat versions of biologic drugs, as Amgen looks to...To view the full article, register now.
Already a subscriber? Click here to view full article